Jonathan Liss, MD
Neurology · Columbus, GANPI 1386613743
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Eisai Inc. at 32.8% of the total. Reporting peaked in 2021 at $67,924 and has fallen 91.5% since, to $5,770 in 2025. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $748.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$104K
- AbbVie$91K
- Biogen$28K
- Pfizer$27K
- Genentech, Inc.$15K
- Genentech USA, Inc.$15K
- plus $39K from 11 others
Across 1,383 payments — averaging $17,888 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$11.3M
- Eli Lilly$6M
- AbbVie$2.1M
- Genentech, Inc.$1.7M
- Roche Diagnostics Operations, Inc.$1.5M
- Biogen$1.3M
- plus $778K from 4 others
What the payments were for
- Consulting fees$135,87843%
- Speaking & faculty fees$153,77048%
- Travel & lodging$22,4507%
- Food & beverage$6,5652%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 133 | $104,476 |
| AbbVie(2 entities) | 123 | $90,576 |
| Biogen | 24 | $27,753 |
| Pfizer | 50 | $27,147 |
| Genentech, Inc. | 11 | $14,976 |
| Genentech USA, Inc. | 18 | $14,868 |
| E.r. Squibb & Sons, L.L.C. | 11 | $9,996 |
| Acadia Pharmaceuticals Inc | 5 | $7,128 |
| Corium, LLC | 16 | $7,110 |
| Merck | 11 | $4,940 |
| F. Hoffmann-la Roche AG | 2 | $4,880 |
| Roche Products Limited | 4 | $4,440 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $179 |
| Lilly USA, LLC | 1 | $107 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Novartis | 2 | $36 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$318,671 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 17 | $17,325 |
| Memantine Hcl | 234 | $9,523 |
| EliquisApixaban | 14 | $8,988 |
| Donepezil Hcl | 629 | $6,746 |
| Sumatriptan Succinate | 25 | $6,154 |
| AdlarityDonepezil Hcl | 13 | $5,758 |
| Levetiracetam | 122 | $5,376 |
| DilantinPhenytoin Sodium Extended | 13 | $2,561 |
| Bupropion XlBupropion Hcl | 75 | $2,366 |
| Quetiapine Fumarate | 84 | $2,176 |
| Lorazepam | 239 | $1,852 |
| Citalopram HbrCitalopram Hydrobromide | 329 | $1,521 |
| Diazepam | 28 | $1,320 |
| Entacapone | 11 | $1,230 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $1,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $90,576 | $17,32517 claims |
| PfizerEliquis, Dilantin | $27,147 | $11,54927 claims |
| Corium, LLCAdlarity | $7,110 | $5,75813 claims |
| Lilly USA, LLCOlanzapine | $107 | $36312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Columbus
- Reinaldo VersonColumbus$98K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Dinesh RajuLawrenceville$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.